Nymox Pharmaceutical Corp
NYMXF- Exchange
- OTC
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001018735
No open-market purchases or sales by Nymox Pharmaceutical Corp insiders were filed in the last 90 days; 1 institution reported holding it in 13F filings for Q2 2026, worth $4.21K in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, 0 vs. previous quarter
- 1
- 13F valueReported value at the end of Q2 2026
- $4.21K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding NYMXF, Q2 2026
No superinvestor reported holding NYMXF at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Nymox Pharmaceutical Corp insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 26, 2023 (view filing)10:27 AM ET | Apr 25-27 | 62 days | Robinson James GeorgeDirector, 10% Owner | PPurchase | +80.0K | $0.46 | +$36.8K | +1.7%4.78M after | Amended2 lots |
| May 6, 2022 (view filing) | May 2 | 4 daysLate | Robinson James GeorgeDirector | PPurchase | +1.15M | $1.65 | +$1.90M | +32.4%4.70M after | |
| May 6, 2022 (view filing) | May 2 | 4 daysLate | Robinson James GeorgeDirector | PPurchase | +1.15M | $0.00 | $0 | –1.15M after | Derivative |
Top 10 13F holders, Q2 2026
The largest institutional positions in Nymox Pharmaceutical Corp at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| First Citizens Financial Corp | 35,100 | $4.21K | 0.00% | 00.0% | Unchanged |